Trial Profile
To Access the pharmacodynamic effect of Cangrelor in patients with Coronory artery disease and treated with Oral P2y12 Receptor Inhibitors
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Dec 2016
Price :
$35
*
At a glance
- Drugs Cangrelor (Primary) ; Prasugrel; Ticagrelor
- Indications Coronary artery disease
- Focus Pharmacodynamics
- 26 Dec 2016 New trial record
- 16 Nov 2016 Results presented at the 89th Annual Scientific Sessions of the American Heart Association